Epperly Melissa B,
SEC CIK 1807359 · EDGAR
BoughtSold
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
| 11 | Epperly Melissa B, | Dir | — | $2.01M |
Transactions 40
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-18 18:56 | 2026-09-16 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +5,054 | 15.0K | +51% | $0 |
| MT | 2026-09-17 18:43 | 2026-09-15 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale | $39.74 | -4,938 | 9,900 | -33% | -$196.2K |
| 2026-09-14 18:34 | 2026-09-10 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | F - Tax | $40.94 | -2,179 | 14.8K | -13% | -$89.2K | |
| 2026-07-21 21:00 | 2026-07-17 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +543 | 17.0K | +3% | $0 | |
| DT | 2026-07-01 18:34 | 2026-06-29 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | M - OptEx | $4.46 | +17.8K | 34.2K | +108% | +$79.2K |
| DMT | 2026-07-01 18:34 | 2026-06-29 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale+OE | $34.38 | -17.8K | 16.5K | -52% | -$610.3K |
| 2026-04-21 18:34 | 2026-04-17 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +670 | 16.5K | +4% | $0 | |
| 2026-03-18 | 2026-03-16 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale | $28.68 | -41.9K | 15.8K | -73% | -$1.20M | |
| 2026-01-22 | 2026-01-20 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | F - Tax | $22.98 | -54 | 57.7K | -0.1% | -$1,241 | |
| 2026-01-22 | 2026-01-20 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +815 | 57.7K | +1% | $0 | |
| 2025-10-22 | 2025-10-20 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,056 | 56.9K | +2% | $0 | |
| D | 2025-09-12 | 2025-09-10 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | J - Other | $13.77 | -1,661 | 55.8K | -3% | -$22.9K |
| D | 2025-09-12 | 2025-09-10 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +14.5K | 57.5K | +34% | $0 |
| 2025-07-21 | 2025-07-17 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,609 | 43.0K | +4% | $0 | |
| 2025-04-21 | 2025-04-17 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,847 | 41.4K | +5% | $0 | |
| 2025-01-27 | 2025-01-23 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | F - Tax | $11.21 | -180 | 39.5K | -0.5% | -$2,018 | |
| 2025-01-27 | 2025-01-23 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,672 | 39.7K | +4% | $0 | |
| 2024-10-23 | 2024-10-21 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,613 | 38.0K | +4% | $0 | |
| 2024-09-16 | 2024-09-12 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | J - Other | $12.12 | -4,245 | 36.4K | -10% | -$51.4K | |
| D | 2024-09-12 | 2024-09-10 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +16.4K | 40.7K | +68% | $0 |
| 2024-07-25 | 2024-07-23 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,702 | 24.3K | +8% | $0 | |
| T | 2024-04-26 | 2024-04-24 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,146 | 22.7K | +5% | $0 |
| T | 2024-04-26 | 2024-04-24 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | F - Tax | $10.90 | -123 | 22.6K | -0.5% | -$1,341 |
| 2024-02-12 | 2024-02-12 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $11.44 | -2,573 | 451.4K | -0.6% | -$29.4K | |
| D | 2024-02-05 | 2024-02-01 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | A - Grant | $0.00 | +75.0K | 462.7K | +19% | $0 |
| D | 2024-02-05 | 2024-02-02 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $11.54 | -8,669 | 454.0K | -2% | -$100.0K |
| 2024-01-23 | 2024-01-19 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,207 | 21.5K | +6% | $0 | |
| 2023-10-18 | 2023-10-16 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,226 | 20.3K | +6% | $0 | |
| M | 2023-10-06 | 2023-10-04 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $19.51 | -5,482 | 388.6K | -1% | -$106.9K |
| D | 2023-09-14 | 2023-09-12 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +17.8K | 19.1K | +1,393% | $0 |
| 2023-07-06 | 2023-07-03 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,280 | 1,280 | New | $0 | |
| M | 2023-02-14 | 2023-02-13+ | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $20.13 | -7,851 | 392.0K | -2% | -$158.0K |
| D | 2023-02-01 | 2023-02-01 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | A - Grant | $0.00 | +102.0K | 399.9K | +34% | $0 |
| 2022-10-03 | 2022-10-03 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | A - Grant | $0.00 | +50.0K | 297.5K | +20% | $0 | |
| M | 2022-04-05 | 2022-04-04 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $50.09 | -17.1K | 256.4K | -6% | -$855.6K |
| M | 2022-02-23 | 2022-02-23 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $49.10 | -1,913 | 264.5K | -0.7% | -$93.9K |
| D | 2022-02-14 | 2022-02-10 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | A - Grant | $0.00 | +16.4K | 266.4K | +7% | $0 |
| 2021-10-04 | 2021-10-02 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | F - Tax | $67.13 | -17.1K | 250.0K | -6% | -$1.15M | |
| M | 2021-08-20 | 2021-08-18+ | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | P - Purchase | $52.00 | +9,611 | 266.7K | +4% | +$499.8K |
| M | 2021-07-06 | 2021-07-01 | ZNTL | Zentalis Pharmaceuticals, Inc. | Epperly Melissa B, | CFO | S - Sale | $51.27 | -3,083 | 257.3K | -1% | -$158.1K |
Purchase Sale Sale after option exercise All abbreviations